A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab rezetecan (Primary)
Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

20 Sep 2024 Planned End Date changed from 1 Dec 2023 to 21 Mar 2026.
20 Sep 2024 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2025.
20 Sep 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight